DMG interpersonal

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Retrieved on: 
Tuesday, November 21, 2023
CNS, DNA, Neoplasm, Metformin, PIK3CA, PI3K, Patient, KZIA, Radiation, Standard of care, MD, Diagnosis, DMG, Survival, ONC201, Female, DIPG, Society, DMG interpersonal, Pharmaceutical industry, Medical imaging

SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting.

Key Points: 
  • SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting.
  • "The 2023 SNO Annual Meeting was another successful event with the latest advances in clinical trials, diagnosis and treatment of pediatric and adult patients with CNS malignancies," stated Dr. John Friend, CEO Kazia.
  • "We are highly encouraged with the preliminary overall survival data from the PNOC022 clinical study that we believe will provide an alternative to the current therapies considered as standard of care."
  • Key paxalisib highlights from the meeting:
    Specifically, the authors observed how ONC201 over activates the PI3K-AKT pathway, which is the target pathway for paxalisib
    Two patient case studies were discussed; each receiving the combination of paxalisib and ONC201 through compassionate access
    Six-year old female with DIPG who received the combination of paxalisib and ONC201 after upfront radiation therapy.

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Retrieved on: 
Wednesday, November 15, 2023
DRD2, Annual general meeting, Therapy, Eosinophilia, Disulfiram-like drug, Lymphocyte, Patient, KZIA, PNOC, Colitis, Mucositis, MD, Trial of the century, Diagnosis, DMG, Hyperglycemia, ONC201, Physician, OS, Society, Hypokalemia, DMG interpersonal, Pharmaceutical industry

The preliminary results from a single cohort in this Pacific Pediatric Neuro-Oncology Consortium (PNOC) sponsored cooperative group clinical study will be presented on Sunday, 19 November 2023 in Vancouver, Canada.

Key Points: 
  • The preliminary results from a single cohort in this Pacific Pediatric Neuro-Oncology Consortium (PNOC) sponsored cooperative group clinical study will be presented on Sunday, 19 November 2023 in Vancouver, Canada.
  • Sixty-eight children and young adults with DMG who completed standard of care radiation treatment received paxalisib (an investigational PI3K-mTOR dual inhibitor) and ONC201 (an investigational dopamine receptor D2 (DRD2) and ClpP agonist).
  • The abstract reported that median overall survival (OS) from time of diagnosis was 16.5 months.
  • "The PNOC022 study has exceeded expectations in terms of enrolment rates and has partnered with 29 leading children's cancer centers and physicians across the globe."

PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY

Retrieved on: 
Thursday, October 6, 2022
DMG interpersonal, GBM, PNOC, ONC201, Diagnosis, RUN, University of California, San Francisco, Neoplasm, NASDAQ, International Symposium on Graph Drawing, Patient, Brain, Research, HIV disease progression rates, University, DRD2, Trial of the century, Marketing, San Francisco, Chad, Diffuse intrinsic pontine glioma, KZIA, Associate, Clinical trial, HMRI, Radiation, Glioblastoma, FDA, Life expectancy, Pharmaceutical industry, Medical imaging, DIPG, Kazia Pelka

DMGs are a group of childhood brain cancers which include DIPG, and which represent approximately 15% of brain tumours in children.

Key Points: 
  • DMGs are a group of childhood brain cancers which include DIPG, and which represent approximately 15% of brain tumours in children.
  • The ongoing PNOC022 study (NCT05009992) combines paxalisib with ONC201, an experimental dopamine receptor D2 (DRD2) antagonist manufactured by Chimerix, Inc. (Durham, NC).
  • "Brain cancer is the leading cause of childhood cancer death, and DMGs represent one of the most challenging types of tumour.
  • In addition, six other clinical trials of paxalisib in other forms of brain cancer are ongoing, with multiple data read-outs anticipated throughout CY2023.

KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE

Retrieved on: 
Tuesday, May 17, 2022
KZIA, Cancer, ET, Disease, Medicine, Diffuse intrinsic pontine glioma, Survival, Multimedia, Brain, NASDAQ, Therapy, Associate, Awareness, DMG interpersonal, ONC201, Research, FDA, Hunter Medical Research Institute, International Symposium on Endovascular Therapy, Leukemia, PNOC, Diagnosis, Pharmaceutical industry, Medical device, DIPG

Around 10-15% of childhood brain cancers are diffuse midline gliomas (DMGs), a group that includes diffuse intrinsic pontine glioma (DIPG).

Key Points: 
  • Around 10-15% of childhood brain cancers are diffuse midline gliomas (DMGs), a group that includes diffuse intrinsic pontine glioma (DIPG).
  • DIPG most commonly affects children between four and eleven years of age.
  • There is currently no FDA-approved therapy for the disease, and median survival is just 9 11 months from diagnosis.
  • Kazia's paxalisib is the subject on an ongoing phase II study in DIPG and DMGs (NCT05009992), sponsored by the Pacific Pediatric Neuro-Oncology Consortium (PNOC).